Docket Number:13A-990614
Inventor:Che-Kun James Shen, Lien-Szu Wu
IP Status:US pending, Issued EP 2400023
Abstract:
Amyotrophic lateral sclerosis (ALS) affects mainly people over 40 with an incident rate of 1-2 per 100, 000. ALS cases often exhibit dementia beside their hall mark symptom of progressive muscular paralysis and atrophy. Mutations in at least 9 different genes, including the long studied superoxide dismutase 1 (SOD 1), have been shown to be associated with 20% of the ALS cases, familial as well as sporadic ones. Currently, there is no drug available for effective treatment of ALS. Significantly, the majority of the ALS cases, including those the disease genes of which have not been identified yet, are signalized with ubiquitinated intracellular inclusions (UBIs) containing the DNA/ RNA-binding protein TDP-43. Biochemical analyses have revealed that TDP-43 is promiscuously modified/ processed in the affected regions of the spinal cords of ALS patients. In addition, immunohistochemistry analysis of the pathological samples from ALS patients has revealed the presence of diseased cells with TDP-43(+) neuronal cytoplasmic inclusions, or NCIs, adjacent to TDP-43-depleted nuclei. These data/ studies suggest that ALS pathogenesis could be caused by loss-of-function of TDP-43, gain of toxicioy from the TDP-43 (+) NCIs, or both. We have generated gene knock-out mouse lines with the TDP-43 expression specifically abolished in their motor neurons.
Fields of Application:
Drug screenign for ALS
Advantages when compared to the existing technologies:
The animal model mimic ALS mark symptom of progressive muscular paralysis and atrophy. It is very helpful to drug screening of ALS.
Contact Person:
對本技術有興趣,請於本處網頁廠商選項下(廠商需求與諮詢)網頁填寫資料,承辦人將跟您聯絡。
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Apply for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office, and the undertaker will contact you.
